Xenon Pharmaceuticals 股價因臨床試驗延遲而下跌
Xenon Pharmaceuticals Shares Fall Following Clinical Trial Delay
Updated at: September 19, 2026 at 03:30 AM
2026年9月17日，Xenon Pharmaceuticals在宣布暫停精神科臨床試驗的新病患入組後，其股價大幅下跌。
On September 17, 2026, Xenon Pharmaceuticals faced a sharp decline in its share price after announcing a temporary pause in new patient enrollment for its psychiatry clinical trials.
該公司正在評估其藥物候選品azetukalner，用於治療重度憂鬱症與雙極性憂鬱症。
The company is evaluating its drug candidate, azetukalner, for major depressive disorder and bipolar depression.
因此，Xenon的股價下跌了近30%，投資人對該公司的精神科藥物研發管線表示擔憂。
Consequently, Xenon’s stock price dropped by nearly 30% as investors expressed concern over the company's psychiatry pipeline.
儘管遭遇挫折，目前的受試者仍將繼續試驗，且公司預計在2027年初公布重度憂鬱症（MDD）研究的結果。
Despite this setback, the trials for current participants continue, and the company expects results for the MDD study by early 2027.
關鍵的是，此情況並未影響Xenon在癲癇領域的研究。
Crucially, the situation does not affect Xenon's work in epilepsy.
在正向進展方面，該公司已向FDA遞交了azetukalner用於治療局部發作性癲癇的新藥申請。
In a positive development, the company submitted a New Drug Application to the FDA for azetukalner as a treatment for focal seizures.
分析師認為，癲癇計畫的安全性數據依然穩固，這為精神科部門的負面消息提供了緩衝。
Analysts believe that the safety data for the epilepsy program remains strong, providing a buffer against the negative news in the psychiatry department.
Xenon目前正在審查潛在的劑量調整，以改善藥物的耐受性，旨在解決安全性問題的同時，持續推進其臨床計畫。
Xenon is now reviewing potential dosing adjustments to improve the drug's tolerability, aiming to address safety issues while maintaining progress in their clinical programs.
